Published in final edited form as:

Mol Cell Endocrinol. 2017 January 5; 439: 74–80. doi:10.1016/j.mce.2016.10.025.

DISORDERED ZONAL AND CELLULAR CYP11B2 ENZYME EXPRESSION IN FAMILIAL HYPERALDOSTERONISM TYPE 3

Celso E. Gomez-Sanchez^{1,2}, Xin Qi², Elise P. Gomez-Sanchez³, Hironobu Sasano⁴, Martin O. Bohlen⁵, and Max Wisgerhof⁶

¹Endocrinology Division, G.V. (Sonny) Montgomery VA Medical Center

²University of Mississippi Medical Center

³Department of Pharmacology and toxicology and Medicine, University of Mississippi Medical Center, Jackson, MS

⁴Department of Pathology, Tohoku University, Sendai, Japan

⁵Department of Anatomical Sciences, University of Mississippi Medical Center, Jackson, MS

⁶Division of Endocrinology, Henry Ford Health System, Detroit, MI

Abstract

Three forms of familial primary aldosteronism have been recognized. Familial Hyperaldosteronism type 1 (FH1) or dexamethasone suppressible hyperaldosteronism, FH2, the most common form of as yet unknown cause(s), and FH3. FH3 is due to activating mutations of the potassium channel gene *KCNJ5* that increase constitutive and angiotensin II-induced aldosterone synthesis. In this study we examined the cellular distribution of CYP11B2, CYP11B1, CYP17A1 and *KCNJ5* in adrenals from two FH3 siblings using immunohistochemistry and immunofluorescence and obtained unexpected results. The adrenals were markedly enlarged with loss of zonation. CYP11B2 was expressed sporadically throughout the adrenal cortex. CYP11B2 was most often expressed by itself, relatively frequently with CYP17A1, and less frequently with CYP11B1. *KCNJ5* was co-expressed with CYP11B2 and in some cells with CYP11B1. This aberrant co-expression of enzymes likely explains the abnormally high secretion rate of the hybrid steroid, 18-oxocortisol.

1.1 Introduction

In 1953 the structure of a highly active mineralocorticoid isolated from the amorphous fraction of beef adrenal extracts (1) was elucidated and named electrocortin (2). It was soon

Address Correspondence: Celso E. Gomez-Sanchez, Division of Endocrinology, University of Mississippi Medical Center, 2500 N. State St, Jackson, MS 39216, 601 368 3844, cgomez-sanchez@umc.edu.

DISCLOSURE SUMMARY: No disclosures.

Disclosures: The authors have nothing to disclose.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

renamed aldosterone by the group of Simpson and Tait in an academic-industry collaboration (3). Just 2 years later Jerome Conn from the University of Michigan described the first clinical case of mineralocorticoid excess due to an aldosterone-producing adenoma (4) and the first description of primary hyperaldosteronism as hypertension, hypokalemia due to potassium wasting in the urine, and hypomagnesemia caused by an aldosterone-producing adrenal adenoma. Primary hyperaldosteronism is now known to have several additional causes including bilateral adrenal hyperplasia, unilateral adrenal hyperplasia, adrenal carcinoma, rare extra-adrenal tumors producing aldosterone, and three familial forms of primary aldosteronism(5). Familial Hyperaldosteronism type 1 (FH1) or Glucocorticoid-Remediable Aldosteronism, the best characterized, is due to a gene duplication resulting from the crossover recombination of the promoter region and first 4 exons of the 11 β -hydroxylase (*Cyp11b1*) and the last exons of the aldosterone synthase (*Cyp11b2*) genes, resulting in a chimeric gene expressed in the zona fasciculata and regulated by ACTH that produces an enzyme that synthesizes aldosterone (6). Familial hyperaldosteronism type 2 (FH2) is the most common FH. While the genetic basis remains unknown, many cases are in linkage with chromosome 7p22 (7, 8). FH3 has been ascribed to an inherited mutation of the *KCNJ5* gene disrupting the selectivity filter of the G-protein activated inward rectifying potassium channel Kir3.4 (9).

1.2. Case reports

In 1959, a 10 year old boy was described with severe hypertension, hypokalemia, polyuria and marked increase in the urinary excretion of aldosterone (9). His severe hypertension could not be controlled with the anti-hypertensive medications available in that era, so he was subjected to bilateral adrenalectomy, resulting in marked improvement of the hypertension, hypokalemia and associated symptoms. His adrenal glands were very large, the right and left adrenals weighing 8.0 and 9.0 g, respectively, with focal nodular hyperplasia and cells of a zona fasciculata phenotype laden with lipid vacuoles (9). Twenty-six years later two of his daughters, ages 7 and 4 years, were found to have severe hypertension, hypokalemic alkalosis, suppressed renin activity, and marked serum aldosterone elevation (10). Administration of dexamethasone resulted in an increase in aldosterone levels, ruling out glucocorticoid-remediable aldosteronism. The patients were lost to follow up for 8 years and presented again with the same clinical manifestations and elevated blood pressure in spite of intensive antihypertensive therapy including spironolactone and/or amiloride and potassium supplements (10). The striking biochemical findings in addition to severe hyperaldosteronism, were marked elevations in the urinary excretion of the hybrid steroids 18-hydroxycortisol and 18-oxo-tetrahydrocortisol, with normal levels of other conventional cortisol metabolites (10). Because the patients' hypertension could not be controlled pharmacologically, including with spironolactone, they underwent bilateral adrenalectomy with normalization of the BP and serum potassium within 2 weeks. The adrenal glands were markedly enlarged with a combined left + right adrenal weight of 81 and 39 g (normal <12 g) and diffuse cortical hyperplasia (10).

1.3. Pathogenesis

A significant advance in our understanding of the pathogenesis of aldosterone-producing adenomas came from the identification of somatic mutations in or near the selectivity filter

of the G-protein coupled potassium channel, Kir3.4 coded by the *KCNJ5* gene (11). Two mutations are most common, G151R and L168R. Sequencing of the *KCNJ5* gene in the family described above (10) revealed a heterozygous T158A mutation in the three affected members (11). This mutation lies between the selectivity filter and the second transmembrane domain of the Kir3.4 potassium channel and results in the loss of potassium selectivity and depolarization of the cell membrane (11). The latter initiates the signals that increase aldosterone synthesis.

We recently described the production of a highly selective mouse monoclonal antibody against the human CYP11B2 and a rat monoclonal antibody against the CYP11B1 enzyme. In this report we describe the adrenal distribution of staining of the CYP11B2 enzyme in the adrenals of the two patients described above and have done triple immunofluorescence of the CYP11B2, CYP11B1 and Kir3.4 potassium channel and triple immunofluorescence of the CYP11B1, CYP11B2 and 17 α -hydroxylase enzyme.

2. Materials and Methods

2.1. Immunohistochemistry

Slides were deparaffinized, subjected to antigen retrieval using a solution of EDTA 1mM and SDS 0.05% pH 9 for 45 min in a steamer, blocked with 5% goat serum in Tris 0.1M and 0.5% SDS at pH 7.4, and immunostained with the mouse monoclonal anti-human CYP11B2-41-17C antibody (1/1000), CYB5 monoclonal antibody (Acris, San Diego) (in tris 0.1 M, tween 20 0.05% with goat serum 5%, as previously reported (12)). A slide was also stained with a specific monoclonal antibody against human HSD3B2 developed in our laboratory (unpublished). The slides were counterstained with hematoxylin.

2.2. Triple Immunofluorescence

After deparaffinizing, antigen retrieval and blocking was done as described above, the slides were incubated overnight at 4C with a mixture of rat monoclonal anti human CYP11B1-80-7 (1/200), mouse monoclonal anti-human CYP11B2-41-17 (1/1,000) (as previously documented (12)), and rabbit anti-17 α -hydroxylase (1/400) (13). The secondary antibodies were goat anti-mouse IgG H&L-Alexa 488, goat anti-rat IgG H&L-Alexa 594 and goat anti-rabbit-Alexa 647 (Jackson ImmunoResearch Inc, Allentown, PA, USA) that have minimal crossreactivity to mouse, human and rat immunoglobulins. Coverslips were mounted using Vector Laboratories Vectashield mounting media with DAPI (Vector Labs, Burlingame, CA, USA). Similar triple immunofluorescence was done with a *KCNJ5* antibody instead of the 17 α -hydroxylase antibody using a sheep antibody from EMD-Millipore (AB9808)(1/10,000) (14) and processed as above. Immunofluorescence for the CYP17A1 (IgG2b), CyB5 (IgG1) and CYP11B2 (IgG1-biotin labeled) were done by incubating for the first two antibodies overnight, washing and incubating with specific goat anti-mouse IgG1-Alexa 488, goat anti-mouse IgG2b-Alexa 594 followed by washing and incubating for 30 min with mouse IgG, washing followed by incubation with mouse monoclonal CYP11B2-41-13B labeled with biotin for 1 hr, washed and incubated with avidin-Oyster 650 for 30 min. After washing they were mounted with Vectashield with DAPI (Vector Laboratories, Burlingame, CA).

3. Results

3.1

Similar to the description of their father's adrenal (10), the adrenals of patients 1 (Fig 1A) and 2 (Fig 1B) stained with hematoxylin and eosin exhibited marked enlargement of the adrenal gland with complete loss of normal zonation composed primarily of lipid laden cells throughout the cortex and no clearly discernable zona glomerulosa type cells. The adrenals of patient 1, Fig 1C, E, G, and that of patient 2, Fig 1D, F, H have CYP11B2 immunoreactivity throughout the cortex in an irregular pattern. CYP11B2 immunoreactive cells are interspersed with cells not expressing the CYP11B2.

Fig 2 shows immunofluorescence of the CYP11B1, CYP11B2 and KCNJ5: overlapped pictures show that cells immunoreactive for CYP11B1 and CYP11B2 are not only interspersed, but both enzymes are co-expressed in some cells. KCNJ5 was co-expressed with CYP11B2 and, in many cells, also with CYP11B1 in contrast to normal adrenals where KCNJ5 is expressed only in cells of the zona glomerulosa (11). Patient 2 showed similar co-expression and mingling of cells expressing CYP11B1 and CYP11B2, however in some areas there was greater co-expression of CYP11B1 with KCNJ5 than CYP11B2 with KCNJ5 (data not shown).

3.2

17 α -Hydroxylase was expressed throughout the adrenal. As expected from normal adrenal zona fasciculata cells, it was expressed in all cells expressing CYP11B1, however, contrary to its normal expression pattern, 17 α -hydroxylase was also found in a significant number of CYP11B2 expressing cells (Fig 3). In some areas 17 α -hydroxylase seemed to be preferentially expressed with CYP11B2. In some cells there was clear expression of the three enzymes.

3.3

HSD3B2 was expressed strongly throughout the adrenal (Fig 4A and C). The cytochrome B5 showed just a few small areas of staining (Fig B and D). Immunofluorescence showed by in those areas CYB5 and CYP17A1 were co-expressed (Fig 4E) and in small areas CYB5 was also co-expressed with CYP11B2 (Fig 4F)

4. Discussion

4.1

Familial hyperaldosteronism type 3 is a rare form of hyperaldosteronism where various mutations of the potassium channel KCNJ5 cause the hypersecretion of aldosterone. The three members of the first family described had extremely severe hypertension and hypokalemia that was not controlled with high doses of spironolactone plus other antihypertensive agents and required a bilateral adrenalectomy for control of the hypertension and electrolyte abnormalities (9, 10). The three patients were heterozygous for the T158A mutation of the *KCNJ5* gene.

4.2

The affected members of this family exhibited a marked increase in the secretion of aldosterone and 18-oxocortisol, but not of cortisol, and the secretion of aldosterone was not suppressed with the administration of dexamethasone (10). CYP17A1 is not normally expressed in the zona glomerulosa. It is co-expressed with CYP11B1 in normal adrenal zona fasciculata cell where their sequential action is required to synthesize cortisol. CYP11B2 is normally expressed only in the zona glomerulosa where it catalyzes the last steps in the synthesis of aldosterone (12). The synthesis of the hybrid steroids 18-hydroxycortisol and 18-oxocortisol requires the sequential action of CYP17A1, then CYP11B2 (15, 16). As the major blood flow in the adrenal gland is centripetal, from the zona glomerulosa, to the fasciculata, on through to the medulla, high concentrations of CYP17A1 products made downstream in the zona fasciculata do not normally become substrates for CYP11B2 directly. As in the normal adrenal there is no evidence of co-expression of these two enzymes, the synthesis of small amounts of 18-hydroxycortisol and 18-oxocortisol is thought to be by zona glomerulosa cells from circulating cortisol (17). In adrenal adenomas and in Familial Hyperaldosteronism type 1, there is a marked increase in the secretion of 18-oxocortisol (16, 18–20). In the case of Familial Hyperaldosteronism type 1, the formation of the chimeric enzyme from the unequal crossing over of the promoter region and first exons of the CYP11B1 and the last exons of the CYP11B2 results in the expression of CYP11B2 in the zona fasciculata where CYP17A1 is also expressed and allows the expression of the hybrid steroids 18-hydroxycortisol and 18-oxocortisol (6, 18). Co-expression of the CYP11B2, CYP11B1 and CYP17A1 enzymes, explains the increased production of the hybrid steroids in some aldosterone-producing adenomas (21). In this study, the CYP11B2 was widely but unevenly expressed throughout the grossly enlarged adrenal and some CYP11B2-positive cells co-expressed both the CYP11B1 and the CYP17A1 enzymes, explaining not only the marked increase in aldosterone, but the highest recorded plasma levels of 18-hydroxycortisol and 18-oxocortisol (10).

In vivo KCNJ5 is normally expressed only in the zona glomerulosa of the adrenal (11) The human adrenal carcinoma HAC15 cell expresses all of the enzymes required to synthesize both aldosterone and cortisol. Transduction with a lentivirus carrying the KCNJ5-T158A mutant resulted in the decrease in the selectivity of the channel, an increase in intracellular sodium, resulting in the mobilization of calcium signaling for a marked increase in the expression of the CYP11B2 enzyme and synthesis of aldosterone (22). As HAC15 cells also express CYP11B1 and CYP17A1, it was not too surprising that the KCNJ5-T158A mutant HAC15 cells also produced significantly more of the hybrid steroid 18-oxocortisol. However the KCNJ5-T158A HAC15 cells also expressed more CYP11B1, in addition to CYP11B2, with no increase in StAR protein required to transport cholesterol in to the mitochondria, the initial step in steroidogenesis, or of other enzymes in the steroidogenic cascades to cortisol or aldosterone. CYP17A1 expression was decreased. While aldosterone production was greatly increased, cortisol was increased only slightly, albeit significantly, as was 18-oxocortisol, in the HAC15 expressing KCNJ5-T158A (22).

KCNJ5 in the adrenals of these FH3 patients was co-expressed with CYP11B2, as expected, but was also abundantly expressed in cells expressing CYP11B1, most of which did not

express detectable CYP11B2. The mechanism that normally limits KCNJ5 expression to zona glomerulosa cells is not known, but these findings suggest that it is not the same as that limiting CYP11B1 and CYP17A1 expression to the zona fasciculata. Nor does the expression of CYP11B2 appear to preclude the expression of CYP17A1. Unfortunately our studies in the HAC15 cells cannot answer these questions of zonal specificity of enzyme expression because they also co-express all of these enzymes. As these patients did not have hypercortisolism, the co-expression of the mutated KCNJ5 either had no effect on CYP11B1 expression, or, if CYP11B1 was increased in these patients' adrenal cells, their cortisol production remained normal due to the appropriate function of the HPA axis and stimulation of StAR protein by ACTH.

4.3

The KCNJ5-T158A mutation resulting in a decreased selectivity of the channel for potassium over sodium results in a very severe syndrome with a grossly enlarged adrenal (9). *In vitro* this mutation causes a slightly less alteration in the selectivity compared to other mutations found in FH3 patients including KCNJ5-G151E or G151R (11),(23, 24). However patients with these more severe KCNJ5 mutations have a milder form of primary aldosteronism probably due to a toxic effect of increased calcium mobilization resulting in an increase in adrenal cell apoptosis and lower mass of the adrenal (24). Multiple families have now been described with germ line mutations of the *KCNJ5* gene including G151E (24, 25), Y152C (26), I157S (27) and several other germ line mutations in patients with sporadic primary aldosteronism (28). A similar picture of heterogeneous expression of the CYP11B2 in a patient with the KCNJ5 Y152C mutation was reported in the supplemental material of the paper of Monticone *et al* (29), but with insufficient details to compare with these two patients. Patients with aldosterone-producing adenomas bearing a KCNJ5 mutation have been shown to have a high expression of CYP11B2, CYP11B1 and CYP17A1 enzymes (30) and these patients as a group excrete high amounts of the hybrid steroids (19). The co-expression of the CYP11B2 and the cytochrome B5 is very abnormal as the latter is only expressed in the zona reticularis (31). It would be interesting to speculate that the co-expression of the CYP11B2, CYP17A1 (which is extensive in these adrenals) and the cytochrome b5 might result in the production of newer steroids that remain to be identified.

4.4

In summary, immunohistochemical analysis of the cellular distribution of steroidogenic enzymes unique to normal zona glomerulosa or fasciculata cells in the grossly hyperplastic adrenal cortex of patients with hyperaldosteronism type 3 reveals the loss of zonation and mingling of cells that express CYP11B2 and/or CYP11B1, with and without CYP17A1, and some that express all three enzymes. KCNJ5 was abundantly expressed in almost all cells, including those that expressed CYP11B1 with no CYP11B2, suggesting that the mutation not only altered the potassium filter selectivity of the channel, but also altered a signal that designated specificity for CYP11B2-expressing cells, or that this family also has a second mutation that abolishes steroidogenic specialization by adrenal zonation.

Acknowledgments

These studies were supported by NIH grant HL27255.

References

1. Grundy HM, Simpson SA, Tait JF. Isolation of a highly active mineralocorticoid from beef adrenal extract. *Nature*. 1952; 169:795–796. [PubMed: 14941045]
2. Simpson SA, Tait JF, Wettstein A, Neher R, Van Euw J, Reichstein T. Isolierung eines neuen kristallisierten hormons aus nebennieren mit besonders hoher wirksamkeit auf den mineralstoffwechsel. *Experientia*. 1953; 9:333–333.
3. Simpson SA, Tait JF, Wettstein A, Neher R, von Euw J, Schindler O, Reichstein T. Konstitution des aldosterons, des neuen mineralocorticoids. *Experientia*. 1953; 10:132–133.
4. Conn JW. Primary aldosteronism, a new clinical syndrome. *J Lab Clin Med*. 1955; 45:3–7. [PubMed: 13233623]
5. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. *Trends Endocrinol Metab*. 2005; 16:114–119. [PubMed: 15808809]
6. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel J-M. A chimaeric 11 β -hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. *Nature*. 1992; 355:262–265. [PubMed: 1731223]
7. Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. *Clin Expt Pharmacol Physiol*. 1992; 19:319–322.
8. Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard PR, Gordon RD, Stratakis CD. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). *J Med Genet*. 2000; 37:831–835. [PubMed: 11073536]
9. Therien B, Mellinger RC, Caldwell JR, Howard PJ. Primary aldosteronism due to adrenal hyperplasia; occurrence in a boy aged 10 years. *AMA J Dis Child*. 1959; 98:90–99. [PubMed: 13660631]
10. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. *The Journal of clinical endocrinology and metabolism*. 2008; 93:3117–3123. [PubMed: 18505761]
11. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Akerstrom G, Wang W, Carling T, Lifton RP. K⁺ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science*. 2011; 331:768–772. [PubMed: 21311022]
12. Gomez-Sanchez CE, Qi X, Velarde-Miranda C, Plonczynski MW, Parker CR, Rainey W, Satoh F, Maekawa T, Nakamura Y, Sasano H, Gomez-Sanchez EP. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. *Molecular and cellular endocrinology*. 2014; 383:111–117. [PubMed: 24325867]
13. Gell JS, Carr BR, Sasano H, Atkins B, Margraf L, Mason JI, Rainey WE. Adrenarche results from development of a 3 β -hydroxysteroid dehydrogenase-deficient adrenal reticularis. *The Journal of clinical endocrinology and metabolism*. 1998; 83:3695–3701. [PubMed: 9768686]
14. Oki K, Plonczynski MW, Lam ML, Gomez-Sanchez EP, Gomez-Sanchez CE. The Potassium Channel, Kir3.4 Participates in Angiotensin II-Stimulated Aldosterone Production by a Human Adrenocortical Cell Line. *Endocrinology*. 2012; 153:4328–4335. [PubMed: 22798349]
15. Ulick S, Chu MD. Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension. *Clin Exper Hyper*. 1982; A4:1771–1777.
16. Ulick S, Chu MD, Land M. Biosynthesis of 18-oxocortisol by aldosterone producing adrenal tissue. *The Journal of biological chemistry*. 1983; 258:5498–5502. [PubMed: 6602132]
17. Freel EM, Shakerdi LA, Friel EC, Wallace AM, Davies E, Fraser R, Connell JM. Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. *The Journal of clinical endocrinology and metabolism*. 2004; 89:4628–4633. [PubMed: 15356073]

18. Gomez-Sanchez CE, Montgomery M, Ganguly A, Holland OB, Gomez-Sanchez EP, Grim CE, Weinberger MH. Elevated urinary excretion of 18-oxocortisol in glucocorticoid suppressible aldosteronism. *The Journal of clinical endocrinology and metabolism*. 1984; 59:1022–1024. [PubMed: 6480807]
19. Mulatero P, di Cella SM, Monticone S, Schiavone D, Manzo M, Mengozzi G, Rabbia F, Terzolo M, Gomez-Sanchez EP, Gomez-Sanchez CE, Veglio F. 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. *The Journal of clinical endocrinology and metabolism*. 2012; 97:881–889. [PubMed: 22238407]
20. Nakamura Y, Satoh F, Morimoto R, Kudo M, Takase K, Gomez-Sanchez CE, Honma S, Okuyama M, Yamashita K, Rainey WE, Sasano H, Ito S. 18-oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism. *The Journal of clinical endocrinology and metabolism*. 2011; 96:E1272–1278. [PubMed: 21593107]
21. Nakamura Y, Maekawa T, Felizola SJ, Satoh F, Qi X, Velarde-Miranda C, Plonczynski MW, Ise K, Kikuchi K, Rainey WE, Gomez-Sanchez EP, Gomez-Sanchez CE, Sasano H. Adrenal CYP11B1/2 expression in primary aldosteronism: Immunohistochemical analysis using novel monoclonal antibodies. *Molecular and cellular endocrinology*. 2014; 392:73–79. [PubMed: 24837548]
22. Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE. Potassium Channel Mutant KCNJ5 T158A Expression in HAC-15 Cells Increases Aldosterone Synthesis. *Endocrinology*. 2012; 153:1774–1782. [PubMed: 22315453]
23. Scholl UI, Lifton RP. New insights into aldosterone-producing adenomas and hereditary aldosteronism: mutations in the K⁺ channel KCNJ5. *Current opinion in nephrology and hypertension*. 2013; 22:141–147. [PubMed: 23318698]
24. Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A, Wang WH, Lifton RP. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. *Proceedings of the National Academy of Sciences of the United States of America*. 2012; 109:2533–2538. [PubMed: 22308486]
25. Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, Fischer E, Tizzani D, Pallauf A, Viola A, Amar L, Williams TA, Strom TM, Graf E, Bandulik S, Penton D, Plouin PF, Warth R, Allolio B, Jeunemaitre X, Veglio F, Reincke M. KCNJ5 Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. *Hypertension*. 2012; 59:235–240. [PubMed: 22203740]
26. Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA, Sterner C, Warth R, Mulatero P, Rainey WE. A Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. *J Clin Endocrinol Metab*. 2013; 98:E1861–1865. [PubMed: 24037882]
27. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki P, Stratakis CA, Chrousos GP. A Novel Point Mutation in the KCNJ5 Gene Causing Primary Hyperaldosteronism and Early-Onset Autosomal Dominant Hypertension. *The Journal of clinical endocrinology and metabolism*. 2012; 97:E1532–1539. [PubMed: 22628607]
28. Murthy M, Xu S, Massimo G, Wolley M, Gordon RD, Stowasser M, O'Shaughnessy KM. Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism. *Hypertension*. 2014; 63:783–789. [PubMed: 24420545]
29. Monticone S, Hattangady NG, Penton D, Isales C, Edwards MA, Williams TA, Sterner C, Warth R, Mulatero P, Rainey WE. A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. *The Journal of clinical endocrinology and metabolism*. 2013
30. Azizan EA, Lam BY, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ, Brown MJ. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. *The Journal of clinical endocrinology and metabolism*. 2012; 97:E819–829. [PubMed: 22442279]
31. Nakamura Y, Xing Y, Hui XG, Kurotaki Y, Ono K, Cohen T, Sasano H, Rainey WE. Human adrenal cells that express both 3 β -hydroxysteroid dehydrogenase type 2 (HSD3B2) and

cytochrome b5 (CYB5A) contribute to adrenal androstenedione production. The Journal of steroid biochemistry and molecular biology. 2011; 123:122–126. [PubMed: 21185375]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Highlights

Immunohistochemistry of 2 cases of familial hyperaldosteronism 3 are described.

CYP11B2 is expressed heterogeneously throughout the adrenal.

CYP11B2 is co-expressed in cells with KCNJ5 and in many cells with CYP11B1.

CYP11B2 is co-expressed in some cells with the 17 α -hydroxylase.

Figure 1. Histology and immunohistochemistry of the adrenals of two patients with Familial Hyperaldosteronism type 3 heterozygous for the KCNJ5-T158A mutation. Panels A, C, E, G: adrenal cortex from patient 1; Panels B, D, F and H adrenal cortex from patient 2. A & B: hematoxylin-eosin staining. C & D. CYP11B2 immunoreactivity throughout the cortex. E & G: sequentially higher magnifications of the boxes in panel C & E of patient 1. F & H: sequentially higher magnifications of the boxes in panel D & F of patient 2.

Figure 2.

Triple immunofluorescence of a section of the adrenal of patient 1 stained with the mouse monoclonal antibody against CYP11B2, rat monoclonal antibody against CYP11B1 and sheep polyclonal antibody against KCNJ5. The panels on the left show the individual staining and nuclear staining with DAPI. The right panels show simultaneous staining of nucleus with DAPI and the combination of antibodies as labeled. Co-expression of the steroidogenic enzymes is indicated by the orange color.

Figure 3.

Immunofluorescence staining of the adrenal of patient 1 with CYP11B1, CYP11B2 and CYP17A1. Panels on the left side are the individual immunoreactivity combined with nuclear staining with DAPI and right panels are overlap pictures of: Top right: CYP11B1 plus CYP11B2 which shows different cells staining for each enzyme and few cells showing co-expression of both enzymes. Middle right: CYP11B2 plus CYP17A1 showing separate cells staining of both enzymes in many cells and in a significant number of cells expressing both enzymes. Lower right panel: CYP11B1 and CYP17A1 showing immunoreactive for either enzyme or both in a significant number.

Figure 4.

Fig 4A and C showed the adrenal of patient 2 stained for HSD3B2 enzyme. Fig 4B and D showed the adrenal of patient 1 stained for the cytochrome B5. Fig 4E shows double immunofluorescence of CYP17A1 and cytochrome B5 in the adrenal of patient 2. Fig 4F shows double immunofluorescence of CYP11B2 and cytochrome B5 of the adrenal of patient 2.